

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EDDING GENOR GROUP HOLDINGS LIMITED

亿腾嘉和醫藥集團有限公司

(formerly known as Genor Biopharma Holdings Limited

嘉和生物藥業(開曼)控股有限公司)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

VOLUNTARY ANNOUNCEMENT PHASE IB/II CLINICAL TRIAL OF GB268 OBTAINED IND APPROVAL BY NMPA

This announcement is made by Edding Genor Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Group about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the Investigational New Drug (“**IND**”) application for the Phase Ib/II clinical trial of GB268, the Company’s highly differentiated and innovative PD-1/CTLA-4/VEGF trispecific antibody, for the treatment of locally advanced unresectable or metastatic breast cancer (including triple-negative breast cancer and hormone receptor-positive/HER2-negative breast cancer) has been approved by the National Medical Products Administration of China (“**NMPA**”).

The NMPA’s approval of this IND was based on the robust monotherapy clinical data and the rational combination mechanism of GB268, demonstrating the favorable safety profile of GB268 as a monotherapy and its potential as a cornerstone in the holistic management of malignant tumors. The indication focuses on locally advanced unresectable or metastatic breast cancer, exploring monotherapy, immunotherapy combined with chemotherapy, and immunotherapy combined with antibody-drug conjugate regimens across first-line and later-line treatment stages, marking the first step in comprehensively expanding the application scope of GB268.

The approval of clinical trial application represents the beginning of exploring combination regimens based on GB268 as an immunotherapy backbone. In the future, the Company also expects to initiate multiple combination therapy clinical studies in additional advanced solid tumor indications.

Currently, the dose-escalation study of GB268 has escalated to 30 mg/kg without dose-limiting toxicity, demonstrating excellent anti-tumor activity and a favorable safety profile. Phase I monotherapy clinical data is expected to be presented at the European Society for Medical Oncology congress in fourth quarter of 2026.

By Order of the Board
Edding Genor Group Holdings Limited
Mr. Ni Xin
Chairman and Executive Director

Hong Kong, 2 July 2026

As of the date of this announcement, the Board comprises Mr. Ni Xin and Dr. Han Shuhua as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.